Sickle Cell Disease.

Slides:



Advertisements
Similar presentations
SICKLE CELL DISEASE Sickle cell anemia.
Advertisements

Sickle Cell Disease Core Concepts for the Emergency Physician and Nurse Epidemiology, Genetics, Pathophysiology Spring 2013 Paula Tanabe, PhD, RN, FAEN,
Sickle cell anemia Clinical vignettes
SICKLE CELL ANEMIA.
Approach to Anemia - Summary
Sickle Cell Anemia Roxbury Community College ADN 253 Honors Presentation Adanna Uwandu, Shadia Laurent, Salwa Said 05/01/07.
Sickle Cell Anemia By: Daniel Lee, Matt Milan, and Min-ki Kim.
What is Sickle Cell Disease?
Hemoglobin Synthesis.  Chromosome 16Chromosome 11 25%  48% 1.5%0.5% 1.5%0.5% Hemoglobin synthesis.
Sickle Cell Anemia Columbia County Medical Assistant Association.
Abdulelah Nuqali Intern. Causes Red cell membrane disorders ( hereditary spherocytosis ) Red cell enzyme disorders ( G6PD deficiency ) Hemoglobinopathies.
Non-Transfusion-Dependent Thalassemia
Sickle cell Disorders1 Sickle Cell Anemia. Sickle cell Disorders2 Sickle Cell Anemia HbS: a 2 ß 2 6Glu Val Sickle cell disorders: sickling with o 2 Sickle.
Sickle Cell Disease: Core Concepts for the Emergency Physician and Nurse Acute Chest Syndrome Spring 2013.
What You Need to Know About Acute Chest Syndrome By Susan Hernandez, RN, CNN, BSN, and G. Elaine Patterson, RN-C, EdD, MA, Med, FPN-C Nursing2009, June.
Tessa Bandhan. Question 1 A 3 year old girl known to have sickle cell disease (Hb SS) presents to the Emergency Room with a 2 day history of weakness.
Chemotherapy/ Biotherapy for Hematology Disease Processes.
Haemoglobinopathies Ahmad Sh. Silmi Msc Haematology, FIBMS.
Sickle Cell Disease Paolo Aquino, M.D., M.P.H., PGY I Combined Internal Medicine/Pediatrics.
Prepared by: Dr. Mazen Basheikh
Sickle Cell Disease Joshua Falto PAs-IV. General Considerations PATHOPHYSIOLOGY 1.A single DNA base change leads to an amino acid substitution of valine.
Hemolytic anemias - Hemoglobinopathies Part 2. Thalassemias Thalassemias are a heterogenous group of genetic disorders –Individuals with homozygous forms.
Sickle-cell anemia By: Cliff Stoutenburg Chemeketa Paramedic Program Sickle Cell.
The Many Faces of Hydroxyurea Soheir Adam, MD. Sickle Cell Disease The commonest genetic disorder in the US Affects about 75,000 individuals Single genetic.
Sickle Cell Disease. Group of genetic disorders characterized by: Hemolytic anemia - not enough red blood cells in the blood Vasculopathy - disorder of.
SICKLE CELL ANEMIA Prepared by: Tuba Kartal Özge Özütrk.
Sickle cell disease This is an inherited multisystem disorder caused by abnormal properties of RBCs containing HbS. This results from mutation in the β-globin.
Clinical aspects of sickle cell and thalassaemia Dr.Beverley Robertson Consultant Haematologist NHS Grampian.
PRESENTED BY ZOE DANIELS
Sickle Cell Disease: Core Concepts for the Emergency Physician and Nurse Epidemiology, Genetics, Pathophysiology Paula Tanabe, PhD, RN, FAEN, FAAN Associate.
Anemia Sickle Cell Anemia.
History 21 y/o AA female presents to ED with abdominal pain.
Sickle Cell Anemia. P. falciparum – Blood stages Uninfected RBC 2 hr. 4 hr. 12 hr.
MARCH 17, 2011 Morning Report. Sickle Cell Disease Chronic hemolytic anemia Multiple hemoglobin variants  SS  SC  S-beta thal One of the most common.
Haemolytic Anaemia Elliot Catchpole PCMD.
By: Glenna, Savannah, and Chris
Haemoglobinopathies.
Elsevier items and derived items © 2008 by Mosby, Inc., an affiliate of Elsevier Inc. Alterations of Hematologic Function in Children Chapter 21.
King Khalid University Hospital Department of Obstetrics & Gynecology Course 481 Anaemia in Pregnancy Anaemia in Pregnancy.
H EMOLYTIC ANEMIAS - H EMOGLOBINOPATHIES Part 2. T HALASSEMIAS Thalassemias are a heterogenous group of genetic disorders Individuals with homozygous.
PHYSIOLOGICAL CHANGES IN PREGNANCY 1.Blood vol.  50% 2. Plasma vol.  disprop. to red cell mass 3. HCT  DEFINITION: Hb < 12-g/dl in non pregnant In.
Epidemiology, Genetics, Pathophysiology Spring 2013
Complications Diagnosis Treatment Introduction Causes symptoms.
MLAB 1415: Hematology Keri Brophy-Martinez
SICKLE CELL DISEASE (scd) By: Yousef Al Sultan Fatimah Al Khamis.
SICKLE CELL ANEMIA Omar and Yassin.
 SCA  Hemoglobin  How it is acquired  Symptoms  What happens in SCA  Treatment.
 Sickle-cell disease results from a single glutamic acid to valine substitution at position 6 of the beta globin polypeptide chain.  It is inherited.
MORNING REPORT TUESDAY, AUGUST 9 TH, Days Smarter!!
Haemoglobinopathies A group of genetic disorders of Hb synthesis characterized by either a reduction of the rate of synthesis of globin chains ( Thalassaemias.
1 Sickle Cell Disease. 2 Bone marrow produces RBCs with defective hemoglobin.
Sickle Cell Disease By Samantha.
  Sickle Cell Disease.
HEMOGLOBIN. DR. Haroon Rashid. Lecture-29. Objectives Describe in detail the structure, synthesis, and catabolism of hemoglobin Explain the different.
Hemoglobinopathies.
Hemoglobin Disorders Sickle cell anemia and Thalassemias Prepared by : Ahmed Ayasa Supervised by :Dr. Abdullateef Al Khateeb 1.
MLAB Hematology Keri Brophy-Martinez Fall 2007 Unit 13: Hemolytic Anemias: Intracorpuscular Defects/ Hemoglobinopathies.
HEMOGLOBINOPATHIES Dr. Swapna V. Goley.
Sickle Cell Anemia Introduction Hereditary disease Hereditary disease Blood disorder Blood disorder Mutation in the Hemoglobin Beta Gene Mutation in.
Hemoglobinopathies, Thalassemias Prof. Dr. S. Sami Kartı.
Sickle Cell Anemia Jeff Bonebrake.  Overview  Signs and Systems  Causes  Risk Factors  Screening and Diagnosis  Complications  Treatment  Prevention.
Hematology/ Fluid Transport
Emily S. Moses, M.D. September 13, 2017
Sickle cell disease -refers to a group of disorders arising from defective genes that produce abnormal Hb molecules (HbS). -Defective genes produce abnormal.
Sickle Cell anemia  .
CURRENT MANAGEMENT OF SCD IN NIGERIA
Hemoglobinopathies in Pregnancy
Molecular medicine ILA
Sickle cell disease -refers to a group of disorders arising from defective genes that produce abnormal Hb molecules (HbS). -Defective genes produce abnormal.
Literature Review Dr. Shaukat Hussain Senior Registrar
Presentation transcript:

Sickle Cell Disease

Introduction Vaso-occlusive phenomena and hemolysis are the clinical hallmarks of Sickle Cell Disease (SCD) Inherited disorder due to homozygosity for the abnormal hemoglobin, hemoglobin S (HbS)

HbS results from substitution of valine for glutamic acid as sixth amino acid of the beta globin chain, which produces a hemoglobin tetramer that is poorly soluble when deoxygenated. Polymer assumes elongated rope-like fiber form in the classic sickle shape

Sickle cell shape results in decrease cell deformability. Changes also occur in red cell membrane structure and function, disordered cell volume control and increase adherence to vascular endothelium.

Overview Disorder most severe in patients with SCD (homozygosity for HbS), of intermediate severity in hemoglobin SC disease (HbSC, combined heterozygosity for hemoglobin S & C), and generally benign in those with sickle cell trait (heterozygosity for Hbs).

Patients with homozygous SCD are typically anemic and often lead a life of painful episodes. Clinical signs and symptoms begin at an early age.

Prevalence of symptoms at age Six month of age - 6% Twelve months of age - 32% Two years of age - 61% Six years of age - 92% eight years of age - 96%

Predictors of adverse outcome Dactylitis before age one Hemoglobin concentration < 7 g/dl Leukocytosis in absence of infection An adverse outcome, defined as stroke, frequent episodes of pain, recurrent acute chest syndrome or death occurred in 18% with these predictors,(392 infants/10yrs).

Laboratory findings Moderate anemia Reticulocytosis 3-15% High MCV Unconjugated hyperbilirubinemia Elevetaed LDH Low haptoglobin Folate & iron deficit Peripheral smear shows sickle cells Polychromasia Howell-jolly bodies Elevated WBC Elevated Platelets Low than after 18 yrs high creatinine

Acute Severe Anemia Acute fall in haptoglobin. Patients present with pallor, weakness and lethargy. Fatalities not uncomon. Due to the Splenic sequestration crisis, aplastic crisis or hyperhemolytic crisis.

Splenic sequestration crisis Vaso-occlusion in the spleen and pooling of blood in the spleen produce fall in hemoglobin, reticulocytosis and rapidly enlarging spleen. Risk of hypovolemic shock and 10-15% mortality. Recurrent in 50% of survivors.

Aplastic crisis Arrest of erythopoiesis with falling hemoglobin levels and absence of reticulocytes. Associated with infection namely Parvo-B19, EBV, Streptococcus and salmonella. Reticulocytes usually reappear in 2-14 days.

Hyperhemolytic crisis Sudden exacerbation of anemia with reticulocytosis. Cause unknown. Rare

Major Clinical Manifestations Acute painful episodes Multiorgan failure Psychosocial issues Growth & development Infection Bacteremia Meningitis Bacterial pneumonia Osteomyelitis CVA Bone complcations Infarct and necrosis Marrow infarct Orbital compression Arthritis

Major Clinical Manifestations Cardiac complications Myocardial infarct Dermatologic complications Leg ulcers Hepatobiliary complications Cholelithiasis Chronic liver disease Acute hepatic episodes Pregnancy complications Fetal complications priapism Pulmonary complications

Major Clinical Manifestations Renal complications Retinopathy Take a deep breath!

Acute painful crisis Precipitated by cold, infection, dehydration, infection, stress, menses, hypoxemia, alcohol or no identifiable cause. Can affect any area, but back, chest, extremities and abdomen most frequent. Usually last 2-7 days. Frequency- 1/3 rarely, 1/3 2-6yr, 1/3>6yr

Acute chest syndrome Due to pneumonia, infarct due to in situ thrombosis and embolic phenomena due to fat embolism and bone marrow infarct. Manifestations are chest pain, infiltrate on CXR and fever. Treat with O2, antibiotics, and exchange transfusion to lower HbS to below 30%.

Management Treatment and prevention of the acute manifestations of SCD. Therapies designed to interfere with the polymerization process at different levels

General principals Regular Physician follow up. Establish base line labs and Physical findings. Education regarding nature of disease, genetic counseling and psychosocial assessment. Immunize for Strep, influenza and Hep B

Prophylactic penicillin until five years. Folic acid 1md/day TCD Retinal evaluation BCP Hydroxyurea

Hdroxyurea Increases production of hemoglobin F. Reduces median crisis rate by 50%, decreased acute chest syndrome and transfusion. 40% reduction in mortality. Mild increase in acute myeloid leukemia

Pain management Narcotics - Morphine or dilaudid Toradol Inhaled nitric oxide anticoagulation low dose INR 1.5 Poloxamer 188

Management of infection Prophylactic fever - Ceftriaxone Acute chest syndrome - Cefuroxime & Erythromycin. Osteomyelitis - Cover salmonella and staph until cultures available.

Transfusion therapy Aplastic crisis Acute chest syndrome or sepsis CVA Priapism Perioperative Simple vs exchange Do not raise Hgb > 10

Prophylactic preoperative transfusion Increase hemoglobin to 10g/dl Reduces serious complications Orthopedic surgery still has 67% serious complications and 17% sickle-related Complications ( acute chest syndrome and vaso-occlusive crises )

Transfusion complications Alloimmunization Iron overload Infection

Prognosis Median age of death for SCD in males is 42 for men and 48 for women Median age of death for Hb SC is 60 for men and 68 for females

Causes of death Infection - 48% Stroke - 10% Complications of therapy - 7 % Splenic sequestration - 7 % Thromboembolism - 5% Renal failure - 4 % Pulmonary hypertension - 3 %

The future Gene therapy Increase expression of Hb F RNA repair Hematopoietic cell transplantation